Celgene Corporation (CELG) Release: Phase III FIRST (MM-020/IFM 07-01) Trial Of REVLIMID® (lenalidomide) Plus Dexamethasone In Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates For Stem Cell Transplant Published In New England Journal Of Medicine
9/4/2014 11:34:19 AM
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that data from FIRST (MM-020/IFM 07-01)—an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant—have been published in the Sept. 4 issue of the New England Journal of Medicine.
Help employers find you! Check out all the jobs and post your resume.
comments powered by